These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1371691)

  • 1. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug.
    Grob PM; Wu JC; Cohen KA; Ingraham RH; Shih CK; Hargrave KD; McTague TL; Merluzzi VJ
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):145-52. PubMed ID: 1371691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase.
    Cohen KA; Hopkins J; Ingraham RH; Pargellis C; Wu JC; Palladino DE; Kinkade P; Warren TC; Rogers S; Adams J
    J Biol Chem; 1991 Aug; 266(22):14670-4. PubMed ID: 1713587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site.
    Wu JC; Warren TC; Adams J; Proudfoot J; Skiles J; Raghavan P; Perry C; Potocki I; Farina PR; Grob PM
    Biochemistry; 1991 Feb; 30(8):2022-6. PubMed ID: 1705436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.
    Klunder JM; Hoermann M; Cywin CL; David E; Brickwood JR; Schwartz R; Barringer KJ; Pauletti D; Shih CK; Erickson DA; Sorge CL; Joseph DP; Hattox SE; Adams J; Grob PM
    J Med Chem; 1998 Jul; 41(16):2960-71. PubMed ID: 9685235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.
    Sardana VV; Emini EA; Gotlib L; Graham DJ; Lineberger DW; Long WJ; Schlabach AJ; Wolfgang JA; Condra JH
    J Biol Chem; 1992 Sep; 267(25):17526-30. PubMed ID: 1381350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
    Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
    J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors.
    Shih CK; Rose JM; Hansen GL; Wu JC; Bacolla A; Griffin JA
    Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9878-82. PubMed ID: 1719542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
    Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
    Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs.
    Bacolla A; Shih CK; Rose JM; Piras G; Warren TC; Grygon CA; Ingraham RH; Cousins RC; Greenwood DJ; Richman D
    J Biol Chem; 1993 Aug; 268(22):16571-7. PubMed ID: 7688367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.
    Smerdon SJ; Jäger J; Wang J; Kohlstaedt LA; Chirino AJ; Friedman JM; Rice PA; Steitz TA
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3911-5. PubMed ID: 7513427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
    Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
    J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
    Richman D; Shih CK; Lowy I; Rose J; Prodanovich P; Goff S; Griffin J
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11241-5. PubMed ID: 1722324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine).
    Skoog MT; Hargrave KD; Miglietta JJ; Kopp EB; Merluzzi VJ
    Med Res Rev; 1992 Jan; 12(1):27-40. PubMed ID: 1371177
    [No Abstract]   [Full Text] [Related]  

  • 14. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
    Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
    Cywin CL; Klunder JM; Hoermann M; Brickwood JR; David E; Grob PM; Schwartz R; Pauletti D; Barringer KJ; Shih CK; Sorge CL; Erickson DA; Joseph DP; Hattox SE
    J Med Chem; 1998 Jul; 41(16):2972-84. PubMed ID: 9685236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.
    Balzarini J; Karlsson A; Pérez-Pérez MJ; Vrang L; Walbers J; Zhang H; Oberg B; Vandamme AM; Camarasa MJ; De Clercq E
    Virology; 1993 Jan; 192(1):246-53. PubMed ID: 7685964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
    Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
    Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors.
    Condra JH; Emini EA; Gotlib L; Graham DJ; Schlabach AJ; Wolfgang JA; Colonno RJ; Sardana VV
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1441-6. PubMed ID: 1380789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.
    Kroeger Smith MB; Rouzer CA; Taneyhill LA; Smith NA; Hughes SH; Boyer PL; Janssen PA; Moereels H; Koymans L; Arnold E
    Protein Sci; 1995 Oct; 4(10):2203-22. PubMed ID: 8535257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.